News & Updates
Filter by Specialty:
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
12 Apr 2022
First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer
First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.
First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer
11 Apr 2022
Aspirin-statin combo lowers hepatocellular carcinoma incidence
Daily use of aspirin reduces the risk of incident hepatocellular carcinoma (HCC), while the combination of daily aspirin use and statin results in a lower incidence of HCC, which suggests a beneficial interaction, according to a study. In addition, no excess oesophageal variceal haemorrhage (VH) is seen among daily aspirin users compared with nonusers.